Kavita Rawat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kavita Rawat has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Ariel Borkowski
Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri
42 shared publications - Bo Peng
Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri
42 shared publications - Brian Andrew Van Tine
Washington University in St. Louis
42 shared publications - Daniel L. J. Thorek
Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri
42 shared publications - Kevin Kim
Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri
42 shared publications - Lindsey M. Kuehm
Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, Missouri
42 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by Elsevier in SSRN Electronic Journal
Natural Antibodies Are the Endogenous Ignitors of Immunity Against Sterile Damage
Damage-associated molecular patterns (DAMPs) arise naturally during tumor development and are deliberately triggered by radiotherapy and immunogenic chemotherapy, both designed to convert tumor injury into adaptive immunity. This conversion fails unpredictably. DAMP-rich tumors frequently remain immune-cold despite abundant calreticulin, HMGB1, and uric acid, and no molecular explanation for this variance has been established. We identify the missing upstream signal, germline- encoded natural antibodies (NAbs). In NAb-deficient mice, lysed neoantigen-expressing cells failed to prime cytotoxic T cells. Immunity was restored by naive or germ-free serum but not by antibody-free Rag1-/- serum. Aicda-/- mice, which retain circulating IgM but cannot class-switch or somatically mutate, mounted CTL responses; Aicda-/-sIgM-/- mice, which lack secreted IgM, did not. Together, these controls establish that the active signal is germline-encoded secreted IgM rather than an adaptively induced antibody response. Purified DAMPs, including monosodium urate, calreticulin, and HMGB1, rendered neoantigens and melanoma antigens immunogenic and reduced metastatic tumor burden, but only in the presence of NAbs, with NLRP3 and CASP1 acting downstream. DAMPs are therefore necessary but not sufficient. Our prior work established that NAbs recognize altered-self surface changes on transforming cells, enabling early elimination before significant DAMP release. The present study reveals a second function: NAbs license the DAMPs released by dying cells through NLRP3 and CASP1, converting sterile damage into immunity. Just as PAMPs are the exogenous ignitors of immunity against infection, NAbs are the endogenous ignitors of immunity against sterile damage.
- 1 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessNatural Antibodies Are the Endogenous Ignitors of Immunity Against Sterile Damage
Damage-associated molecular patterns (DAMPs) arise naturally during tumor development and are deliberately triggered by radiotherapy and immunogenic chemotherapy, both designed to convert tumor injury into adaptive immunity. This conversion fails unpredictably. DAMP-rich tumors frequently remain immune-cold despite abundant calreticulin, HMGB1, and uric acid, and no molecular explanation for this variance has been established. We identify the missing upstream signal, germline- encoded natural antibodies (NAbs). In NAb-deficient mice, lysed neoantigen-expressing cells failed to prime cytotoxic T cells. Immunity was restored by naive or germ-free serum but not by antibody-free Rag1-/- serum. Aicda-/- mice, which retain circulating IgM but cannot class-switch or somatically mutate, mounted CTL responses; Aicda-/-sIgM-/- mice, which lack secreted IgM, did not. Together, these controls establish that the active signal is germline-encoded secreted IgM rather than an adaptively induced antibody response. Purified DAMPs, including monosodium urate, calreticulin, and HMGB1, rendered neoantigens and melanoma antigens immunogenic and reduced metastatic tumor burden, but only in the presence of NAbs, with NLRP3 and CASP1 acting downstream. DAMPs are therefore necessary but not sufficient. Our prior work established that NAbs recognize altered-self surface changes on transforming cells, enabling early elimination before significant DAMP release. The present study reveals a second function: NAbs license the DAMPs released by dying cells through NLRP3 and CASP1, converting sterile damage into immunity. Just as PAMPs are the exogenous ignitors of immunity against infection, NAbs are the endogenous ignitors of immunity against sterile damage.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance
Correlation plots between PSA and sip-T subsets
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance
Correlation plots between PSA and sip-T subsets
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance
IL-15 treatment of sip-T significantly improves their cytotoxicity (determined by incucyte) against prostate tumors
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance
IL-15 treatment of sip-T significantly improves their cytotoxicity (determined by incucyte) against prostate tumors
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance
CyTOF analysis of various immune checkpoint molecules in sip-T subsets
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance
CyTOF analysis of various immune checkpoint molecules in sip-T subsets
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance
IL-15 expands antigen-specific T-cell subsets of sip-T
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance
IL-15 expands antigen-specific T-cell subsets of sip-T
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance
IL-15 significantly improves sip-T mediated suppression of tumor growth in vivo
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance
IL-15 significantly improves sip-T mediated suppression of tumor growth in vivo
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance
IL-15 significantly improves activation of sip-T in peripheral blood in vivo
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance
IL-15 significantly improves activation of sip-T in peripheral blood in vivo
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S12 from High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance
Correlation plots between clinical outcomes and sip-T subsets
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance
Correlation plots between clinical outcomes and sip-T subsets
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S11 from High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance
Correlation plots between overall survival and sip-T subsets
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance
Correlation plots between overall survival and sip-T subsets